Faisal Ghiath Sukhtian, Director at Outlook Therapeutics, Inc. (OTLK), bought 30,000 shares at $1.29 ($39K) on 2022-10-07, disclosed to the SEC on 2022-10-11.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| OTLK | BUY | 2021-12-02 | $25K | — | Filing → |
| OTLK | BUY | 2021-04-20 | $18K | — | Filing → |
| OTLK | BUY | 2020-09-17 | $7K | — | Filing → |